Lisa Carey, MD, of the University of North Carolina, discusses heterogeneity, treatment response, and outcome in HER2-positive breast cancer.
Jean-Yves Douillard, MD, PhD, of Centre R Gauducheau, reviews new clinical trials and data on systemic and radiation treatment of small cell lung cancer.
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discusses this prospective study of endocrine therapy alone in patients with ER-positive, HER2-negative, node-negative breast cancer (Abstract 5BA).
Martine J. Piccart-Gebhart, MD, PhD, of the Jules Bordet Institute, discusses the ESMO initiative to make cancer drugs affordable.
Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).
Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, discusses results of the phase III METEOR trial in advanced renal cell carcinoma, which evaluated the efficacy of cabozantinib compared to everolimus in patients with disease progression after VEGFR-targeted therapy (Abstract 4LBA).
